RBDCOV, towards a new COVID-19 vaccine for children, adolescents and immunocompromised people using a recombinant protein

RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the variants of COVID19

What is RBDCOV ​

RBDCOV is a clinical trial that tests how efficient, tolerable, in terms of side-effects, and safe, the HIPRA’s vaccine against the different variants of COVID-19 by the consortium partners. The Covid-19 vaccine being developed by HIPRA is an adjuvanted recombinant protein vaccine, based on a receptor binding domain (RBD) fusion heterodimer containing variants B.1.1.7 (alpha) and B.1.351 (beta) of SARS-CoV-2.

The initiative is an innovative vaccine-focused research project that brings together the expertise of a number of European groups and companies in rational design of animal and human vaccine immunogens, vaccine manufacturing, distribution and commercialisation, cellular and humoral immune responses, clinical trials, regulatory issues, stakeholders involvement and patients perspective.

As we all know, COVID-19 is a respiratory disease categorized by the WHO as a pandemic that has provoked obviously a health crisis, but a socio-economic crisis too because of the measured needed and adopted by the different countries to try to contain the spread of the virus.

rbdcov vaccine researcher lab

News

Choose a country:

Recruitment forms

Don't miss the opportunity to be part of the solution!

Participate in the clinical trial and helps to fulfil the purpose of the project: to offer a new tool to control the pandemic at short-medium and long term, and to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe

Our partners

Contact

Press Office

Contact us for general information

Susana Garayoa sgarayoa@zabala.eu
Phone number: M (+32) 484 61 91 64
(Brussels)

Amaia Cabezón acabezon@zabala.es
Phone number: M (+34) 673 744 542
(Pamplona)